MADRID, Nov. 18, 2026 /PRNewswire/ — Gene Solutions hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid biopsy technologies and the clinical and real-world data generated in Asia with the international oncology community. The achievement reflects the company’s evolution from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-free DNA technologies spanning cancer screening, precision oncology, and functional applications.

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026
ESMO Congress, one of the world’s leading oncology meetings, brought together more than 40,000 participants from the global cancer community in Madrid in 2026 for the largest congress in ESMO’s history. The meeting provided a platform for scientific exchange on advances in precision oncology.
The symposium, titled "AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation," was attended at full capacity and convened internationally recognized experts, including Prof. Umberto Malapelle, President of the International Society of Liquid Biopsy and Professor at the University of Naples Federico II; Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong; Prof. Aya El Helali of The University of Hong Kong; Dr. Le Son Tran and Dr. Vien Le of the Medical Genetics Institute; and Asst. Prof. Lucksamon Thamlikitkul of Siriraj Hospital, Mahidol University.
The program reviewed multi-omic technologies and evidence from Asia, encompassing both prospective clinical studies and real-world datasets. Sessions focused on challenges and future directions in multi-cancer early detection, comprehensive genomic and transcriptomic profiling, longitudinal ctDNA monitoring, and immune profiling as well as functional patient-derived organoid models for evaluating treatment response to support therapeutic decision-making.
Discussions across the presentations highlighted the value of integrating complementary multi-omic approaches rather than relying on any single technology. Drawing on clinical validation and real-world experience generated in Asia, Gene Solutions’ patient-centered ecosystem was highlighted, connecting earlier detection, comprehensive genomic profiling, deeper biological and immune understanding, functional investigation of treatment response, and longitudinal circulating tumor DNA monitoring around the needs of the same patient. The approach is intended to support more individualized care while addressing the practical requirements of implementation across diverse healthcare settings.

A patient-centered precision oncology ecosystem integrating earlier detection, genomic profiling, multi-omic and immune insights, functional testing, and ctDNA monitoring.
Reflecting on the symposium discussions, Prof. Umberto Malapelle, President of the International Society of Liquid Biopsy, emphasized the growing significance of multi-cancer early detection:
"We discussed how the cancer-screening landscape is evolving and the potential role of multi-cancer early detection. MCED assays represent one of the key weapons in this battle against cancer. The technology is now available, promising data are emerging from different settings, and the next step is to generate the prospective evidence needed to demonstrate clinical utility and support appropriate implementation."
Beyond early detection, symposium discussions also addressed how advanced molecular technologies can be translated into routine cancer care across diverse healthcare systems.
As Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong commented:
"Liquid biopsy can extend access to accurate genomic profiling in settings where access to tissue-based testing may be limited. Combining liquid and tissue approaches improves the completeness of molecular information available for monitoring, diagnosis, and treatment selection, while generating data that may be relevant beyond the Asian region."
The symposium also highlighted how precision oncology is evolving beyond genomic alterations alone toward a more comprehensive understanding of disease biology.
Prof. Aya El Helali of The University of Hong Kong said:
"Precision oncology increasingly requires a multilayered understanding of disease, integrating genomic, transcriptomic, epigenetic, proteomic, and immune-related information. Bringing these insights together with functional models such as patient-derived organoids may help prioritize more individualized and evidence-driven treatment strategies."
Gene Solutions and the Medical Genetics Institute also contributed two posters presenting real-world research from Southeast Asia on tissue and liquid-biopsy molecular profiling and longitudinal ctDNA monitoring across multiple cancer types.
Beyond the scientific program, the company’s exhibition area facilitated discussions with oncologists, molecular pathologists, translational researchers, laboratory leaders, healthcare institutions, pharma and industry colleagues throughout the conference.
Commenting on Gene Solutions’ participation at ESMO Congress 2026, Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, said:
"The discussions underscored both the progress made in applying multi-omic liquid biopsy approaches in clinical practice and the remaining challenges in supporting broader access. Our focus remains on advancing technologies that can deliver clinically useful information — from earlier detection to treatment selection and disease monitoring — across different healthcare settings."
For Gene Solutions, ESMO Congress 2026 represented more than a successful scientific event. It marked an important step in a journey that began in Asia and continues to grow through a commitment to innovations that support earlier cancer detection, more precise treatment decisions, deeper biological understanding, and more effective disease monitoring for patients worldwide.
Watch the faculty presentations and interviews, view the panel discussion, and explore Gene Solutions’ scientific posters at: https://www.genesolutions.com/inside-gene-solutions-esmo-2026-symposium-and-scientific-program-six-perspectives-across-the-cancer-care-continuum/
About Gene Solutions
Gene Solutions is a global biotechnology company advancing precision cell-free DNA solutions across cancer detection (SPOT-MAS), precision oncology (K-TRACK, K-4CARE), and pregnancy care (triSure). By combining multi-omic science, data intelligence and a scalable technology platform, Gene Solutions brings world-class genomics closer to clinicians and patients, expanding access to clinically meaningful innovation around the world.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network